All Photos(1)

Key Documents

COO/COA

View All Documentation

E-067

Ethosuximide solution

Name: Ethosuximide solution
Brand: CERILLIAN

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₇H₁₁NO₂

CAS Number:

77-67-8

Molecular Weight:

141.17

EC Number:

200-659-6

UNSPSC Code:

41116107

grade

certified reference material

Quality Level

300

feature

Snap-N-Spike^®/Snap-N-Shoot^®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant^®

concentration

1.0 mg/mL in methanol

format

single component solution

storage temp.

−20°C

SMILES string

CCC1(C)CC(=O)NC1=O

InChI

1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

InChI key

HAPOVYFOVVWLRS-UHFFFAOYSA-N

Gene Information

human ... CACNA1G(8913) , CACNA1H(8912) , CACNA1I(8911)

General description

Ethosuximide is an anticonvulsant specifically used to treat absence seizures. This Snap-N-Spike^® Reference Solution is suitable for LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.

Description

Pricing

Signal Word

Danger

Hazard Statements

H225,H301 + H311 + H331,H370

Precautionary Statements

P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ethosuximide modifies network excitability in the rat entorhinal cortex via an increase in GABA release.

Stuart D Greenhill et al.

Neuropharmacology, 62(2), 807-814 (2011-09-29)

Ethosuximide is the drug of choice for treating generalized absence seizures, but its mechanism of action is still a matter of debate. It has long been thought to act by disrupting a thalamic focus via blockade of T-type channels and

Effects of fluoxetine on the anticonvulsant action of valproate and ethosuximide in mouse model of myoclonic convulsions.

Kinga K Borowicz et al.

Annals of agricultural and environmental medicine : AAEM, 19(3), 487-490 (2012-10-02)

Depression is becoming a growing problem in rural areas. This psychiatric disorder often accompanies epilepsy. The aim of this study was to assess the influence of fluoxetine (FXT), a commonly used antidepressant, on the protective action of two conventional antiepileptic

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.

Tracy A Glauser et al.

Epilepsia, 54(1), 141-155 (2012-11-22)

Determine the optimal initial monotherapy for children with newly diagnosed childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. A double-blind, randomized controlled clinical trial compared the efficacy, tolerability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine

Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome.

V Vidal et al.

Neuroscience, 220, 158-168 (2012-06-26)

The Ts65Dn (TS) mouse model of Down syndrome (DS) displays a number of behavioral, neuromorphological and neurochemical phenotypes of the syndrome. Altered GABAergic transmission appears to contribute to the mechanisms responsible for the cognitive impairments in TS mice. Increased functional

Ethosuximide-induced mania in a 10-year-old boy.

Joseph Chien

Epilepsy & behavior : E&B, 21(4), 483-485 (2011-06-22)

Psychosis and suicidal ideation have been reported as side effects of ethosuximide treatment, but previous reports seldom place these symptoms in the context of mania. Given the recent renewed interest in ethosuximide as first-line therapy in children and adolescents, it

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service